In this presentation from the “CDK 4/6 Inhibitor Therapy for ER+ Metastatic Breast Cancer – Advancing Nursing Care to Improve Patient Outcomes” symposium held during the 2016 Annual Meeting of the Oncology Nursing Society, Austin Kershner discusses how to council ER+ metastatic breast cancer patients on the safety expectations and side effects of CDK 4/6 inhibitors.
Earn accreditation for this activity at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=7208
© 2016 Imedex, LLC.
Advertisement